/
COCH
$0.68+$0.02 (+2.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$51.3M
77M shares
52-week range
$0.36 – $1.89
21% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
5.95%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4.12
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $310.0K | $237.0K | $316.0K | $225.0K | $241.0K |
| Cost of revenue | $0 | $769.0K | $498.0K | $789.0K | $742.0K | $874.0K |
| Gross profit | $0 | −$459.0K | −$261.0K | −$473.0K | −$517.0K | −$633.0K |
| Gross margin | — | -148.1% | -110.1% | -149.7% | -229.8% | -262.7% |
| R&D | $0 | $3.9M | $5.0M | $9.0M | $10.2M | $12.5M |
| Operating income | −$701 | −$6.9M | −$8.7M | −$18.4M | −$19.3M | −$22.3M |
| EBITDA | −$701 | −$8.6M | −$15.8M | −$29.8M | −$19.8M | −$21.9M |
| Net income | −$701 | −$8.7M | −$15.9M | −$29.9M | −$20.8M | −$23.8M |
| Net margin | — | -2798.4% | -6718.6% | -9469.0% | -9242.2% | -9857.3% |
| EPS (diluted) | 0.00 | -1.05 | -1.57 | -2.54 | -1.49 | -1.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $200000 | $-0.30 | $-0.30–$-0.30 | 1 |
| 2027 | $14M | $-0.19 | $-0.19–$-0.19 | 1 |
| 2028 | $44M | $0.46 | $0.46–$0.46 | 1 |
| 2029 | $90M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.03
Price
$0.68
Implied downside
-96%
Peer comparison
Envoy Medical, Inc. Class A Common Stock
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
www.envoymedical.com- Employees
- 47
- IPO / List date
- Oct 2, 2023
- HQ
- WHITE BEAR LAKE, MN
Held by traders on TradeandTell
No one on the platform currently holds COCH.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in COCH as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded COCH yet.
